297 related articles for article (PubMed ID: 10942515)
1. Retinoids and ovarian cancer.
Zhang D; Holmes WF; Wu S; Soprano DR; Soprano KJ
J Cell Physiol; 2000 Oct; 185(1):1-20. PubMed ID: 10942515
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors.
Holmes WF; Dawson MI; Soprano RD; Soprano KJ
J Cell Physiol; 2000 Oct; 185(1):61-7. PubMed ID: 10942519
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR.
Holmes WF; Soprano DR; Soprano KJ
J Cell Biochem; 2003 May; 89(2):262-78. PubMed ID: 12704790
[TBL] [Abstract][Full Text] [Related]
4. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
[TBL] [Abstract][Full Text] [Related]
5. GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells.
Jiang T; Soprano DR; Soprano KJ
J Cell Physiol; 2007 Sep; 212(3):771-9. PubMed ID: 17474084
[TBL] [Abstract][Full Text] [Related]
6. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines.
Holmes WF; Soprano DR; Soprano KJ
J Cell Physiol; 2004 Jun; 199(3):317-29. PubMed ID: 15095280
[TBL] [Abstract][Full Text] [Related]
7. Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
Soprano KJ; Purev E; Vuocolo S; Soprano DR
Oncogene; 2006 Aug; 25(38):5315-25. PubMed ID: 16936753
[TBL] [Abstract][Full Text] [Related]
8. Classical and novel retinoids: their targets in cancer therapy.
Fontana JA; Rishi AK
Leukemia; 2002 Apr; 16(4):463-72. PubMed ID: 11960323
[TBL] [Abstract][Full Text] [Related]
9. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
10. Synthetic retinoid fenretinide in breast cancer chemoprevention.
Bonanni B; Lazzeroni M; Veronesi U
Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
[TBL] [Abstract][Full Text] [Related]
11. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
12. Fenretinide and its relation to cancer.
Ulukaya E; Wood EJ
Cancer Treat Rev; 1999 Aug; 25(4):229-35. PubMed ID: 10448131
[TBL] [Abstract][Full Text] [Related]
13. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity.
Dawson MI; Hobbs PD; Peterson VJ; Leid M; Lange CW; Feng KC; Chen Gq ; Gu J; Li H; Kolluri SK; Zhang Xk ; Zhang Y; Fontana JA
Cancer Res; 2001 Jun; 61(12):4723-30. PubMed ID: 11406543
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials with retinoids for breast cancer chemoprevention.
Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
18. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade.
Wu K; DuPré E; Kim H; Tin-U CK; Bissonnette RP; Lamph WW; Brown PH
Breast Cancer Res Treat; 2006 Mar; 96(2):147-57. PubMed ID: 16273314
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line.
Holmes WF; Soprano DR; Soprano KJ
J Biol Chem; 2002 Nov; 277(47):45408-19. PubMed ID: 12237293
[TBL] [Abstract][Full Text] [Related]
20. Retinoids: present role and future potential.
Evans TR; Kaye SB
Br J Cancer; 1999 Apr; 80(1-2):1-8. PubMed ID: 10389969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
